The use of patient reported outcome measures (PROMs) in clinical assessment. [PDF]
Black+20 more
core +1 more source
This study develops a semi‐supervised classifier integrating multi‐genomic data (1404 training/5893 validation samples) to improve homologous recombination deficiency (HRD) detection in breast cancer. Our method demonstrates prognostic value and predicts chemotherapy/PARP inhibitor sensitivity in HRD+ tumours.
Rong Zhu+12 more
wiley +1 more source
Patient-Reported Outcome Measures in Safety Event Reporting: PROSPER Consortium Guidance [PDF]
core +1 more source
This nationwide study evaluated KRAS and NRAS mutations in 10 754 Turkish patients with metastatic colorectal cancer. The results revealed a mutation frequency of 51.1%, with 46.6% having KRAS mutations, 4.5% having NRAS mutations, and 48.5% being wild‐type for both.
Gozde Kavgaci+6 more
wiley +1 more source
The Development and Validation of a Multidimensional Sum-Scaling Questionnaire to Measure Patient-Reported Outcomes in Acute Respiratory Tract Infections in Primary Care: The Acute Respiratory Tract Infection Questionnaire [PDF]
Rune Aabenhus+3 more
openalex +1 more source
Weakly supervised text classification on free-text comments in patient-reported outcome measures. [PDF]
Linton AG+4 more
europepmc +1 more source
Landscape of BRAF transcript variants in human cancer
We investigate the annotation of BRAF variants, focusing on protein‐coding BRAF‐220 (formerly BRAF‐reference) and BRAF‐204 (BRAF‐X1). The IsoWorm pipeline allows us to quantify these variants in human cancer, starting from RNA‐sequencing data. BRAF‐204 is more abundant than BRAF‐220 and impacts patient survival.
Maurizio S. Podda+5 more
wiley +1 more source
Patient-Reported Outcome Measures for Systemic Lupus Erythematosus Clinical Trials: A Content Validity and Psychometric Performance Review [PDF]
L. Humphrey+6 more
openalex +1 more source
Communication Patient Reported Outcome Measures for Adults With Communication Disorders: A Systematic Review of Content Validity. [PDF]
Van Ewijk L+3 more
europepmc +1 more source
Loss of proton‐sensing GPR4 reduces tumor progression in mouse models of colon cancer
G protein‐coupled receptor 4 (GPR4) is a pH‐sensing receptor activated by acidic pH. GPR4 expression is increased in patients with inflammatory bowel disease who are at high risk of developing colorectal cancer. In mouse models, loss of GPR4 attenuated tumor progression. This correlated with increased IL2 and natural killer cell activity.
Leonie Perren+16 more
wiley +1 more source